Evozyne vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Evozyne applies generative AI and evolutionary principles to design novel therapeutic proteins; raised $144M total including $81M Series B led by Fidelity and OrbiMed with NVIDIA NVentures participation; 54 employees; Chicago-based.
About
Evozyne is a Chicago-based biotechnology company founded in 2020 by Andrew Ferguson and Rama Ranganathan that uses generative AI to design novel, high-performance proteins for therapeutic and commercial applications. The company occupies a distinctive position at the frontier of AI-driven drug discovery: unlike companies that apply AI to screen existing molecule libraries or predict protein folding (like AlphaFold), Evozyne generates entirely new protein sequences from scratch using its proprietary understanding of evolutionary sequence-function relationships. These de novo proteins are designed with specific functional properties for therapeutic development or industrial applications.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.